Ozempic

Page 7 of 8

tube of wegovy injections
Lifestyle

Novo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy 

By
March 8, 2024
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.
Retail

Novo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year, country’s largest bank says

By Niclas Rolander and Bloomberg
March 5, 2024
WHO
Health

A billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says

By Naomi Kresge, Angela Feliciano and Bloomberg
March 1, 2024
Meta CEO and cofounder Mark Zuckerberg
Tech

All the tech layoffs are because AI is like ‘corporate Ozempic’—it trims the fat and you keep the fact you’re using it a secret, says marketing guru Scott Galloway

By
February 29, 2024
A man walking in front of Sweetgreen
Retail

Meet the surprise winner of the Ozempic craze: a fast-casual chain selling $18 salads

By Madison Muller and Bloomberg
February 21, 2024
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
Retail

Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge

By
February 8, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
Retail

Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them

By
February 5, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail

Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year

By
January 31, 2024
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
Health

North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030

By Simone Foxman, Madison Muller and Bloomberg
January 27, 2024
Ozempic is getting more popular—and more expensive
Health

Ozempic is getting more popular—and more expensive

By
January 18, 2024
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
Health

Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’

By Ellie Harmsworth and Bloomberg
December 24, 2023
Ozempic manufactured by Novo Nordisk packaging on December 7, 2023.
Health

Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival

By Christian Wienberg and Bloomberg
December 13, 2023
Weight loss drugs are all the rage.
Health

Pfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro

By Madison Muller and Bloomberg
December 1, 2023
Lars Fruergaard Jorgensen holding a microphone in one hand and paper flashcards in the other hand
Health

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

By
November 27, 2023
Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’
Health

Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’

By Jonel Aleccia and The Associated Press
November 20, 2023

Most Popular